RxDoctor Payments Data

Michael Rotman, MD

Urology · Lawrence, NYNPI 1649284100

Payments from drug & device makers

$18,029in general payments, 2019–2025

Across 367 payments — averaging $49.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acerus Pharmaceuticals Corporation$6K
  • Aytu Biopharma, Inc.$3K
  • Astellas Pharma US Inc$2K
  • Teleflex LLC$1K
  • Johnson & Johnson$1K
  • Neotract Inc.$597
  • plus $4K from 34 others

What the payments were for

  • Consulting fees$8,12545%
  • Travel & lodging$4172%
  • Food & beverage$8,49147%
  • Education$9966%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,029 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$272,212
Medicare patients
471
Services billed
2,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate121$656,120
XtandiEnzalutamide38$529,270
ErleadaApalutamide17$251,564
MyrbetriqMirabegron133$63,686
GemtesaVibegron54$32,789
Tamsulosin Hcl800$11,868
Silodosin83$9,078
Solifenacin Succinate202$8,728
Testosterone34$8,350
Finasteride433$4,573
Potassium Citrate ErPotassium Citrate18$1,909
Testosterone Cypionate41$1,840
Estradiol17$1,505
Tolterodine Tartrate ErTolterodine Tartrate30$1,466
Trospium Chloride38$1,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$152$656,120121 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,556$592,956171 claims
Johnson & JohnsonErleada$1,203$251,56417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.

Other urology in Lawrence

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →